FOLFOX and Altuzan (Bevacizumab) Treatment Regimen for Colon Cancer
Reading tools
In this article
FOLFOX + Bevacizumabis a standard combination for metastatic colorectal cancer (mCRC), bringing together chemotherapy (5-FU/Leucovorin/Oxaliplatin) and antiangiogenic treatment (Bevacizumab), with efficacy demonstrated in multicenter trials. It aims to suppress tumor cell proliferation and vascularization simultaneously.
What Is FOLFOX + Bevacizumab, and How Does It Work?
- 5-FU: thymidylate synthase inhibition and impaired RNA/DNA synthesis → proliferation stops, apoptosis increases.
- Leucovorin: stabilizes 5-FU binding to thymidylate synthase → greater 5-FU activity.
- Oxaliplatin: DNA crosslinks and adducts → cell-cycle arrest and cell death.
- Bevacizumab: VEGF-A binding/inactivation → reduced vascular permeability, suppressed neoangiogenesis, and “vascular normalization” that may improve intratumoral chemotherapy penetration.
Note: The vascular normalization window may affect chemotherapy efficacy and toxicity in some patients.
Treatment Goals
- Reduce tumor burden and extend survival (targeting OS and PFS gains).
- Control symptoms (pain, obstruction, bleeding, improved performance status).
- In selected cases, increase the chance of conversion (potential resection) , particularly with limited liver metastases.
- With a stable response, manage toxicity by transitioning to maintenance strategies (e.g., 5-FU±Bevacizumab).
Indication and Guideline Position
- Metastatic colorectal cancer (mCRC), 1st line: Recommended regardless of RAS/BRAF status. Left-sided, RAS-wild type patients: select in comparison with anti-EGFR therapy; right-sided/RAS-mutant patients: an anti-VEGF combination is considered clinically more rational than anti-EGFR.
- Later lines: FOLFOX-bev may be reused/sequenced according to previous treatments and clinical context.
- Guidelines: NCCN (v.2025) and ESMO (2022) recommend FOLFOX + Bevacizumab with strong evidence.
Türkiye: Reimbursed by SGK for colorectal cancer; check local indication/file requirements at each institution.
Dose and Administration Order (Cycles Every 14 Days)
- Bevacizumab 5 mg/kg IV (usually before chemotherapy; first infusion 90 minutes, then 30–60 minutes)
- Oxaliplatin 85 mg/m² IV over 2 hours (Day 1)
- Leucovorin 400 mg/m² IV over 2 hours (Day 1; Y-site administration with oxaliplatin)
- 5-FU bolus 400 mg/m² IV (Day 1) → followed by 5-FU infusion 2400 mg/m² over 46 hours (discharge with a portable port pump)
Antiemetics/premedication: Oxaliplatin is moderately emetogenic → 5-HT3 antagonist + dexamethasone ± NK1 antagonist (per institutional protocol). Consider a longer infusion with a history of neuropathy.
Pretreatment Checks and Between-Visit Monitoring
- Laboratory: Complete blood count, creatinine/eGFR, AST/ALT/ALP/bilirubin, electrolytes; baseline urine protein (dipstick) ± 24-hour protein.
- Vital signs: Blood pressure (check before Bevacizumab), weight/performance status.
- DPD assessment: Pharmacogenetic/activity testing with prior severe 5-FU toxicity or in high-risk groups.
- Imaging: Baseline CT/MRI; response assessment every 8–12 weeks.
- Monitoring frequency: Laboratory tests + blood pressure before each cycle; repeat proteinuria assessment every 1–2 cycles.
Precautions During Administration
- Infusion reactions: Close monitoring, particularly during the first Bevacizumab and oxaliplatin infusions.
- Cold sensitivity: Acute oxaliplatin neuropathy → avoid cold drinks/contact during and after infusion.
- Pump management: The 46-hour 5-FU pump requires education on line care, flow checks, leakage, and skin irritation.
- Hypertension: Pre-Bevacizumab BP target generally <140/90 mmHg; delay/adjust for uncontrolled hypertension.
- Proteinuria: For +1 or higher, measure 24-hour protein; consider interruption/discontinuation at ≥2 g/24 h.
Selected Drug Interactions
- 5-FU – Warfarin: Increased INR → more frequent monitoring, dose adjustment.
- 5-FU – Brivudine/Sorivudine: Fatal toxicity through DPD inhibition (contraindicated; allow a safe interval).
- Oxaliplatin – Aminoglycosides/Loop diuretics: Potentially increased nephrotoxicity/ototoxicity.
- Bevacizumab – Anticoagulants/Antiplatelets: Bleeding risk ↑ → assess benefit–risk and monitor closely.
- Blood pressure medication interactions: ACEi/ARB/CCB can manage Bevacizumab hypertension (a coadministration note rather than an interaction).
Special Situations Requiring Caution
- Planned surgery: Allow an interval after the last Bevacizumab dose of ≥6 weeks (wound-healing/bleeding risk).
- IBD or active diverticulitis: Select Bevacizumab very cautiously because of gastrointestinal perforation risk.
- History of thromboembolism: Manage anticoagulation according to severity and risk profile, balancing bleeding risk.
- Older/frail patients: Initial 5-FU dose reduction or omission of the bolus; close neuropathy monitoring.
- Renal impairment: Plan oxaliplatin dosing intervals according to total cumulative dose; caution in severe impairment.
- Cardiac disease: 5-FU-related ischemic events; joint cardiology follow-up.
- Pregnancy: Bevacizumab is teratogenic/embryotoxic; in pregnancy, contraindicated.
Approach to Dose Modification
| Situation | Recommendation | Note |
|---|---|---|
| Cumulative oxaliplatin neuropathy (≥G2) | Reduce dose / temporarily stop; “stop-and-go” (FOLFOX → 5-FU±Bev maintenance) | Until symptoms reverse; consider persistent neuropathy risk |
| Severe 5-FU mucositis/diarrhea | Temporarily stop + support; reduce by 20-25% in the next cycle | Address dehydration/electrolyte disturbances |
| Bevacizumab ≥G3 hypertension | Delay until controlled; adjust antihypertensives | Consider discontinuation if refractory |
| ≥2 g/24 h proteinuria | Withhold Bevacizumab; reassess after improvement | Nephrology advice may be needed |
| Gastrointestinal perforation / Serious bleeding | Bevacizumab permanently discontinue | Emergency management, surgery, and support |
Actual dose changes must follow institutional protocols and individual patient factors.
Side-Effect Frequency and Practical Tips
>20% Common %10–20 Frequent %1–10 Less frequent <%1 Rare/serious
5-Fluorouracil
| Frequency | Side effect | Tip |
|---|---|---|
| >20% | Mucositis, hand–foot syndrome, diarrhea | Oral hygiene, urea–salicylic creams; early loperamide; hydration |
| %10–20 | Myelosuppression, nausea/vomiting | Antiemetic prophylaxis; seek help early for signs of infection |
| %1–10 | Skin rash, transaminases ↑ | Symptomatic treatment; review dose if persistent |
| <%1 | Cardiotoxicity (ischemia, spasm) | Stop immediately for chest pain; emergency cardiology assessment |
Oxaliplatin
| Frequency | Side effect | Tip |
|---|---|---|
| >20% | Acute cold-related paresthesia, cramps | Avoid cold drinks/food/contact; prolong infusion |
| %10–20 | Chronic sensorimotor neuropathy | Stop-and-go; reduce/stop for symptoms ≥G2 |
| %1–10 | Allergic reactions | Premedication; slow or stop infusion for reactions |
| <%1 | Anaphylaxis, pulmonary toxicity | Emergency protocol; permanent discontinuation |
Bevacizumab
| Frequency | Side effect | Tip |
|---|---|---|
| >20% | Hypertension, epistaxis (mild) | Monitor BP; add antihypertensives; local measures for epistaxis |
| %10–20 | Proteinuria, delayed wound healing | Dipstick/24h; ≥6-week interval for surgery |
| %1–10 | VTE/ATE (less common) | Prophylaxis/anticoagulation according to risk factors |
| <%1 | Gastrointestinal perforation, serious bleeding, PRES | Emergency assessment; permanently discontinue Bevacizumab |
Frequencies vary by study and combination; interpret alongside individual risks and guidelines.
FOLFOX + Bevacizumab is a 1st-line colorectal cancer option supported by strong evidence. Appropriate selection (tumor side, molecular status), careful toxicity management, and timely maintenance/sequencing strategies improve long-term control. Proactive monitoring, particularly for neuropathy and vascular risks, is decisive for success.
References
1) Hurwitz H, et al. Bevacizumab with chemotherapy in mCRC. N Engl J Med 2004.
2) NCCN Clinical Practice Guidelines in Oncology: Colon/Rectal Cancer, v.2025.
3) Van Cutsem E, Cervantes A, et al. ESMO Guidelines: Metastatic CRC. Ann Oncol 2022.
4) André T, et al. Oxaliplatin-based regimens and neuropathy management. J Clin Oncol 2020.
5) Grothey A, et al. Maintenance strategies with fluoropyrimidine ± Bevacizumab in mCRC. J Clin Oncol 2012 & subsequent updates.
6) T.C. Sağlık Bakanlığı – SGK Geri Ödeme Listeleri (2025).
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.